全文获取类型
收费全文 | 605篇 |
免费 | 61篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 21篇 |
妇产科学 | 9篇 |
基础医学 | 39篇 |
口腔科学 | 35篇 |
临床医学 | 61篇 |
内科学 | 148篇 |
皮肤病学 | 9篇 |
神经病学 | 25篇 |
特种医学 | 107篇 |
外科学 | 57篇 |
综合类 | 66篇 |
预防医学 | 40篇 |
眼科学 | 8篇 |
药学 | 26篇 |
中国医学 | 4篇 |
肿瘤学 | 16篇 |
出版年
2022年 | 5篇 |
2021年 | 10篇 |
2020年 | 7篇 |
2019年 | 6篇 |
2018年 | 18篇 |
2017年 | 13篇 |
2016年 | 13篇 |
2015年 | 17篇 |
2014年 | 20篇 |
2013年 | 31篇 |
2012年 | 23篇 |
2011年 | 25篇 |
2010年 | 45篇 |
2009年 | 31篇 |
2008年 | 26篇 |
2007年 | 23篇 |
2006年 | 32篇 |
2005年 | 19篇 |
2004年 | 17篇 |
2003年 | 14篇 |
2002年 | 14篇 |
2001年 | 6篇 |
2000年 | 16篇 |
1999年 | 6篇 |
1998年 | 17篇 |
1997年 | 18篇 |
1996年 | 18篇 |
1995年 | 17篇 |
1994年 | 17篇 |
1993年 | 19篇 |
1992年 | 3篇 |
1991年 | 4篇 |
1990年 | 7篇 |
1989年 | 11篇 |
1988年 | 10篇 |
1987年 | 7篇 |
1986年 | 8篇 |
1985年 | 12篇 |
1984年 | 5篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1981年 | 8篇 |
1980年 | 4篇 |
1979年 | 3篇 |
1978年 | 3篇 |
1977年 | 6篇 |
1976年 | 5篇 |
1975年 | 8篇 |
1973年 | 3篇 |
1966年 | 3篇 |
排序方式: 共有672条查询结果,搜索用时 15 毫秒
71.
本文对药物流产时在不同时间加用不同剂量的紫草对药物流产效果的影响进行探索。紫草的加用时间为米索前列醇 (简称米索 )应用前 3d、后 3d及前后共 6 d,剂量分别为 5 0 g、75 g和 1 0 0 g。 1 35 0例早孕妇女分成 9个研究组进行观察。结果表明 :在米索应用前 3d和前后 6 d加用紫草效果较米索应用后 3d加用紫草在完全流产率和出血时间两方面效果明显改善 (P均 <0 .0 5 )。紫草用量 5 0~ 1 0 0 g时流产效果与紫草剂量无明显相关。因此我们认为药物流产时在应用米索前紫草与米非司酮同时应用效果较好 ,剂量以5 0 g较为合理 相似文献
72.
73.
Needle-localized breast biopsy: why do we fail? 总被引:10,自引:0,他引:10
74.
TRAIL-receptor expression is an independent prognostic factor for survival in patients
with a primary glioblastoma multiforme 总被引:1,自引:0,他引:1
Kuijlen JM Mooij JJ Platteel I Hoving EW van der Graaf WT Span MM Hollema H den Dunnen WF 《Journal of neuro-oncology》2006,78(2):161-171
SummaryPurpose In order to improve the survival of patients with a glioblastoma multiforme tumor (GBM), new therapeutic strategies must be developed. The use of a death inducing ligand such as TRAIL (TNF Related Apoptosis Inducing Ligand) seems a promising innovative therapy. The aim of this study was to quantify the expression of the death regulating receptors TRAIL-R1, TRAIL-R2 and TRAIL on primary GBM specimens and to correlate this expression with survival.Experimental design Expression of TRAIL and TRAIL-receptors was assessed by immunohistochemistry, both quantitatively (% of positive tumor cells) and semi-quantitatively (staining intensity) within both the perinecrotic and intermediate tumor zones of primary GBM specimens. RT-PCR of GBM tissue was performed to show expression of TRAIL receptor mRNA.Results Immunohistochemistry showed a slight diffuse intracytoplasmic and a stronger membranous staining for TRAIL and TRAIL receptors in tumor cells. Semi-quantitative expression of TRAIL showed a significantly higher expression of TRAIL in the perinecrotic zone than in the intermediate zone of the tumor (P=0.0001). TRAIL-R2 expression was significantly higher expressed than TRAIL-R1 (P=0.005). The antigenic load of TRAIL-R2 was positively correlated with survival (P=0.02). Multivariate analysis of TRAIL-R1 within the study group (n=62) showed that age, gender, staining intensity, antigenic load, % of TRAIL-R1 expression, were not statistically correlated with survival however radiotherapy was significantly correlated (multivariate analysis: age: P=0.15; gender: P=0.64; staining intensity: P=0.17; antigenic load: P=0.056; % of TRAIL-R1 expression: P=0.058; radiotherapy: P=0.0001). Subgroup analysis of patients who had received radiotherapy (n=47) showed a significant association of % of TRAIL-R1 expression and the antigenic load of TRAIL-R1 with survival (multivariate analysis: P=0.036, respectively, P=0.023).Multivariate analysis of TRAIL-R2 staining intensity and antigenic load, within the study group (P=0.004, respectively, P=0.03) and the subgroup (P=0.002, respectively, P=0.004), showed a significant association with survival. RT-PCR analysis detected a negative relation between the amount of TRAIL-R1 mRNA and the WHO grade of astrocytic tumors (P=0.03).Conclusions TRAIL-R1 and TRAIL-R2 expression on tumor cells are independent prognostic factors for survival in patients with a glioblastoma multiforme. Both receptors could be targets for TRAIL therapy. As TRAIL-R2 is more expressed, in comparison with TRAIL-R1, on GBM tumor cells, TRAIL-R2 seems to be of more importance as a target for future TRAIL therapy than TRAIL-R1. 相似文献
75.
α-葡萄糖苷酶抑制剂治疗2型糖尿病的系统评价 总被引:4,自引:0,他引:4
目的评价α-葡萄糖苷酶抑制剂治疗2型糖尿病患者的效果。方法检索Cochrane图书馆、MEDLINE、EMBASE、CurrentContents、LILACS在研试验数据库,主题为α-葡萄糖苷酶抑制剂的综述的参考文献,并联系纳入试验的专家与实施者。最近检索日期为2003年月12月(CurrentContents)和2003年4月(其他数据库)。纳入α-葡萄糖苷酶抑制剂单一疗法与其它干预比较,治疗2型糖尿病疗程至少12周的随机对照试验,并且试验至少包括以下结局之一:病死率、患病率、生活质量、血糖控制、血脂、胰岛素水平、体重、不良事件。两名评价者独立阅读所有摘要,评价质量并提取数据,分歧通过协商解决或由第三位评价者裁决。由一位统计学家在对提取数据输入数据库时进行检查。我们尽量联系所有作者以核实数据。结果共纳入41个试验、8130例受试者,其中30个针对阿卡波糖,7个针对米格列醇,1个针对优格列波糖,还有3个为不同α-葡萄糖苷酶抑制剂间的比较。绝大多数研究疗程为24周,仅有2个研究超过1年。与安慰剂相比,阿卡波糖血糖控制效果更好:糖化血红蛋白–0.8%[95%CI(–0.9,–0.7)],空腹血糖–1.1mmol/L[95%CI(–1.4,–0.9)],负荷血糖–2.3mmol/L[95%CI(–2.7,–1.9)],阿卡波糖对糖化血红蛋白的作用呈非剂量依赖。我们发现其可降低负荷胰岛素,但对血脂和体重未见临床相关的作用。不良反应主要来自胃肠道且与剂量相关。相对于磺脲,阿卡波糖将空腹和负荷胰岛素水平分别降低至–24.8pmol/L[95%CI(–43.3,–6.3)]和–133.2pmol/L[95%CI(–184.5,–81.8)],但阿卡波糖引起的不良反应更多。结论关于α-葡萄糖苷酶抑制剂是否影响2型糖尿病患者的病死率和患病率仍不清楚。相反,其对血糖控制或胰岛素水平作用明显,对血脂和体重的作用差异无统计学意义。α-葡萄糖苷酶抑制剂更长疗程的效果仍不确定。阿卡波糖剂量超过50mg(TID)时不能进一步影响糖化血红蛋白水平,不良反应反而更多,与磺脲相比,α-葡萄糖苷酶抑制剂降低了空腹和负荷胰岛素水平,但在血糖控制和不良反应方面存在不利影响。 相似文献
76.
The magnetic resonance (MR) relaxation rates of protons were compared in the myelinated and nonmyelinated nerves of the garfish. The long, large olfactory nerve of the garfish, as an easily accessible source of nonmyelinated axons, is uniquely suited for such a comparison. The T1 and T2 measurements revealed distinct and consistent differences between nonmyelinated olfactory nerves and myelinated optic and oculomotor nerves. Comparisons between water content, lipid content, and relaxation rates indicated that the differences in MR properties represent complex differences in the distribution and physical environment of the constituent lipid and water protons. 相似文献
77.
78.
U. Rüb H. Heinsen† E. R. Brunt‡ B. Landwehrmeyer§ W. FA Den Dunnen¶ K. Gierga T. Deller 《Neuropathology and applied neurobiology》2009,35(1):4-15
Recent progress in oculomotor research has enabled new insights into the functional neuroanatomy of the human premotor oculomotor brainstem network. In the present review, we provide an overview of its functional neuroanatomy and summarize the broad range of oculomotor dysfunctions that may occur in Huntington's disease (HD) patients. Although some of these oculomotor symptoms point to an involvement of the premotor oculomotor brainstem network in HD, no systematic analysis of this functional system has yet been performed in brains of HD patients. Therefore, its exact contribution to oculomotor symptoms in HD remains unclear. A possible strategy to clarify this issue is the use of unconventional 100-µm-thick serial tissue sections stained for Nissl substance and lipofuscin pigment (Nissl-pigment stain according to Braak). This technique makes it possible to identify the known nuclei of the premotor oculomotor brainstem network and to study their possible involvement in the neurodegenerative process. Studies applying this morphological approach and using the current knowledge regarding the functional neuroanatomy of this human premotor oculomotor brainstem network will help to elucidate the anatomical basis of the large spectrum of oculomotor dysfunctions that are observed in HD patients. This knowledge may aid clinicians in the diagnosis and monitoring of the disease. 相似文献
79.
80.